Retinitis Pigmentosa Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Allergan, Amarantus Bioscienc, Amgen, Astellas Pharma, jCyte and Others.

April 19 19:33 2021
Retinitis Pigmentosa Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Allergan, Amarantus Bioscienc, Amgen, Astellas Pharma, jCyte and Others.

Retinitis Pigmentosa Pipeline

Retinitis Pigmentosa comprises a large group of inherited vision disorders that cause progressive degeneration of the retina, the light sensitive membrane that coats the inside of the eyes. Peripheral (or side) vision gradually decreases and eventually is lost in most cases. Central vision is usually preserved until late in these conditions.

DelveInsight’s, Retinitis Pigmentosa Pipeline Insights, 2021,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Retinitis pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Request for free sample report: https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight

 

Some of Retinitis Pigmentosa Companies are:

  • Acucela Inc
  • Allergan Plc
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Applied Genetic Technologies Corp
  • Asklepios BioPharmaceutical Inc
  • Astellas Pharma Inc
  • Caladrius Biosciences Inc
  • Dompe Farmaceutici SpA
  • GenSight Biologics SA
  • Grupo Ferrer Internacional SA
  • ID Pharma Co Ltd
  • Janssen Pharmaceutical
  • MeiraGTx
  • Anabasis Pharma
  • Allegro Ophthalmics
  • Nacuity Pharmaceuticals
  • ReNeuron
  • jCyte
  • Editas Medicine
  • SanBio
  • Nightstar Therapeutics/Biogen
  • OiDE OptoEye
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight

 

DelveInsight’s Retinitis Pigmentosa report covers around 30+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Retinitis Pigmentosa Drugs are:

  • Cenegermin
  • LCA10 program
  • SB623:
  • Risuteganib
  • NPI 001
  • ReN 003
  • jCell
  • GtCCR4 gene therapy
  • AAV8-RPGR/BIIB112
  • EDIT 102
  • SB 623
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Retinitis pigmentosa: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Retinitis pigmentosa – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Retinitis pigmentosa Collaboration Deals

• Comparative Analysis

AAV8-RPGR/BIIB112: Nightstar Therapeutics/Biogen

Mid Stage Products (Phase II)

• Comparative Analysis

ReN 003: ReNeuron

jCell: jCyte

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Risuteganib: Allegro Ophthalmics

NPI 001: Nacuity Pharmaceuticals

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

LCA10 program: Editas Medicine

SB623: SanBio

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Retinitis pigmentosa Key Companies

Retinitis pigmentosa Key Products

Retinitis pigmentosa- Unmet Needs

Retinitis pigmentosa- Market Drivers and Barriers

Retinitis pigmentosa- Future Perspectives and Conclusion

Retinitis pigmentosa Analyst Views

Retinitis pigmentosa Key Companies

Appendix

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight